House Bill 192, also known as the "Individualized Investigational Treatment Act," amends Tennessee law to establish a framework for the use of individualized investigational treatments for patients with life-threatening or severely debilitating illnesses. The bill defines key terms such as "eligible facility," "eligible patient," and "individualized investigational treatment," and outlines the criteria that patients must meet to qualify for such treatments. It mandates that patients provide written, informed consent that includes detailed information about their condition, treatment options, potential outcomes, and financial responsibilities. The bill also clarifies that manufacturers are not required to provide these treatments and that costs associated with them may fall to the patient.

Additionally, the bill protects healthcare providers from disciplinary actions based solely on their recommendations for individualized investigational treatments and ensures that state officials cannot obstruct patient access to these treatments. It specifies that patients' heirs will not be liable for debts related to the treatment if the patient dies, and it establishes that there is no private cause of action against manufacturers or providers for harm resulting from these treatments, provided they comply with the law. The act is set to take effect on July 1, 2025.